Aclaris Reports Q1 Revenue of $2M, Beating Consensus
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy ACRS?
Reports Q1 revenue $2M, consensus $1.32M. "Since the start of 2026, we have made great progress toward our goal of developing best-in-class compounds to address a variety of immuno-inflammatory diseases," stated Dr. Neal Walker, Chief Executive Officer and Chair of the Board of Directors of Aclaris. "Most recently, the positive results from our Phase 1a SAD/MAD trial of our bispecific antibody ATI-052 confirmed its potential as having a best-in-class PK/PD profile with an extended dosing schedule of up to every three months. We look forward to an exciting rest of the year with expected milestones including delivery of placebo-controlled top line results from our Phase 1b proof-of-concept trials of ATI-052 in both asthma and atopic dermatitis and the Phase 2 trial of our anti-TSLP monoclonal antibody bosakitug in atopic dermatitis."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ACRS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ACRS
Wall Street analysts forecast ACRS stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.930
Low
8.00
Averages
11.33
High
16.00
Current: 4.930
Low
8.00
Averages
11.33
High
16.00
About ACRS
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing novel small and large molecule product candidates for immuno-inflammatory diseases. Its proprietary KINect drug discovery platform coupled with its integrated discovery approach to small and large molecules enables the Company to identify and advance product candidates. It provides contract research services to third parties enabled by its early-stage research and development expertise. The contract research segment is engaged in the provision of laboratory services. Its product candidate pipeline includes Bosakitug (ATI-045), ATI-2138 and ATI-052. The Bosakitug (ATI-045) is an investigational, novel, humanized anti-Thymic stromal lymphopoietin (TSLP) monoclonal antibody that specifically binds to human TSLP, blocking its interaction with the receptor complex and disrupting signal transduction. Its other investigational product candidate is Lepzacitinib (ATI-1777).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Aclaris Therapeutics Q1 Earnings Beat Expectations
- Earnings Highlights: Aclaris Therapeutics reported a Q1 GAAP EPS of -$0.15, beating expectations by $0.01, indicating a trend towards improved profitability.
- Revenue Growth: The company achieved $2M in revenue for Q1, representing a 37% year-over-year increase and exceeding market expectations by $0.68M, reflecting sustained demand for its products and boosting market confidence.
- Clinical Progress: Aclaris has made positive strides in its clinical programs for lead bispecific antibody candidates, further solidifying its competitive position in the biopharmaceutical sector.
- Market Reaction: Despite a GAAP EPS of -$0.16, missing expectations by $0.02, the overall financial performance still demonstrates the company's potential for growth in challenging conditions, likely attracting more investor interest.
See More
Aclaris' Phase 1a Trial Results Exceed Expectations for ATI-052
- Clinical Trial Results: Aclaris' ATI-052 antibody demonstrated a best-in-class pharmacokinetic profile in Phase 1a trials, with an estimated half-life of approximately 45 days, supporting a potential three-month dosing schedule that opens new avenues for treating immuno-inflammatory diseases.
- Efficacy Validation: ATI-052 showed complete and sustained inhibition of TSLP and IL-4 induced CCL17, indicating a potential efficacy ceiling in Th2-driven diseases, which could significantly enhance patient quality of life.
- Future Research Plans: Aclaris intends to initiate a Phase 2b trial for ATI-052 in Q4 2026 and a phased study for ATI-2138 targeting lichen planus later this year, reflecting the company's ongoing commitment and strategic positioning in immunotherapy.
- Market Opportunity: ATI-2138 is expected to address an unmet need in the treatment of lichen planus, with a potential market opportunity exceeding $1 billion, underscoring Aclaris' strategic importance in fulfilling medical demands.
See More
Aclaris Therapeutics to Release Key Clinical Results
- Clinical Results Announcement: Aclaris Therapeutics is set to release clinical results for two of its leading immuno-inflammatory drug candidates before the U.S. market opens on April 28, 2026, marking a significant update in the company's biologic and oral inhibitor pipeline.
- Research Progress: The company will provide full results from its Phase 1a single and multiple ascending dose study of ATI-052, along with the lead indication selection for ATI-2138, demonstrating its ongoing commitment to research and development in immunotherapy.
- Stock Price Movement: Over the past year, ACRS has traded between $1.16 and $4.89, closing at $4.41 on Monday with a 2.56% increase, indicating positive market sentiment ahead of the upcoming results.
- Trading Activity: In after-hours trading, ACRS shares rose to $4.55, up 3.17%, reflecting investor confidence in the company's future prospects and heightened interest in the clinical results.
See More
Aclaris to Announce Phase 1a Trial Results Tomorrow
- Clinical Trial Results Announcement: Aclaris Therapeutics will announce the results of its Phase 1a trial for the anti-TSLP/IL-4R bispecific antibody ATI-052 before market opening on April 28, 2026, which is expected to provide critical clinical data that could influence the company's future R&D direction.
- Lead Indication Selection Process: The company will also disclose the results of its lead indication selection process for the ITK/JAK3 inhibitor ATI-2138, information that will help the market assess the potential of its product pipeline and may boost investor confidence.
- Webcast Arrangement: Aclaris will host a webcast and conference call at 8:30 AM EST on April 28, 2026, to provide detailed interpretations of the clinical data, enhancing communication with investors and increasing transparency.
- Caution on Forward-Looking Statements: The company cautions investors about the risks associated with forward-looking statements, including uncertainties in clinical trials and reliance on third parties, which could lead to significant discrepancies between actual results and expectations, impacting stock price volatility.
See More
Aclaris to Participate in Inflammatory Skin Disease Conference
- Executive Participation: Aclaris' CEO Neal Walker and senior leadership will participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference on April 14, 2026, showcasing the company's advancements in immuno-inflammatory diseases and aiming to enhance investor and public awareness of its R&D pipeline.
- Webcast Availability: The event will be accessible via a live and archived webcast on Aclaris' website for at least 30 days post-event, providing investors with convenient access to information and enhancing the company's transparency and public trust.
- R&D Pipeline Focus: Aclaris is dedicated to developing novel product candidates for immuno-inflammatory diseases, addressing the urgent need for effective treatment options, which highlights the company's innovative capabilities and market potential in the biopharmaceutical sector.
- Strategic Positioning: By participating in such industry conferences, Aclaris not only showcases its R&D strength but also strengthens connections with investors and industry experts, paving the way for future financing and collaboration opportunities.
See More
Aclaris Reports Significant Clinical Results for ATI-2138 in Atopic Dermatitis
- Significant Clinical Outcomes: At the 2026 American Academy of Dermatology Annual Meeting, Aclaris reported that patients receiving ATI-2138 showed a 77% improvement in Eczema Area and Severity Index (EASI) scores over 12 weeks, highlighting the drug's potential in treating atopic dermatitis.
- Multiple Metrics Improvement: The treatment group experienced a 70% improvement in affected body surface area, a 50% reduction in Peak Pruritus Numerical Rating Scale (PP-NRS) scores, and a 65% enhancement in Dermatology Life Quality Index (DLQI), further validating ATI-2138's broad applicability in immuno-inflammatory diseases.
- Good Tolerability: ATI-2138 demonstrated excellent tolerability at a low dose of 10 mg BID, achieving near-complete ITK target occupancy, which may reduce drug burden and enhance dosing flexibility for patients.
- Research and Development Potential: Aclaris's pipeline indicates that ATI-2138 is not only effective in atopic dermatitis but also holds promise for other immune-inflammatory diseases reliant on T cell function, supporting its potential as a best-in-class therapy.
See More
Aclaris Therapeutics Q1 Earnings Beat Expectations
- Earnings Highlights: Aclaris Therapeutics reported a Q1 GAAP EPS of -$0.15, beating expectations by $0.01, indicating a trend towards improved profitability.
- Revenue Growth: The company achieved $2M in revenue for Q1, representing a 37% year-over-year increase and exceeding market expectations by $0.68M, reflecting sustained demand for its products and boosting market confidence.
- Clinical Progress: Aclaris has made positive strides in its clinical programs for lead bispecific antibody candidates, further solidifying its competitive position in the biopharmaceutical sector.
- Market Reaction: Despite a GAAP EPS of -$0.16, missing expectations by $0.02, the overall financial performance still demonstrates the company's potential for growth in challenging conditions, likely attracting more investor interest.
See More
Aclaris' Phase 1a Trial Results Exceed Expectations for ATI-052
- Clinical Trial Results: Aclaris' ATI-052 antibody demonstrated a best-in-class pharmacokinetic profile in Phase 1a trials, with an estimated half-life of approximately 45 days, supporting a potential three-month dosing schedule that opens new avenues for treating immuno-inflammatory diseases.
- Efficacy Validation: ATI-052 showed complete and sustained inhibition of TSLP and IL-4 induced CCL17, indicating a potential efficacy ceiling in Th2-driven diseases, which could significantly enhance patient quality of life.
- Future Research Plans: Aclaris intends to initiate a Phase 2b trial for ATI-052 in Q4 2026 and a phased study for ATI-2138 targeting lichen planus later this year, reflecting the company's ongoing commitment and strategic positioning in immunotherapy.
- Market Opportunity: ATI-2138 is expected to address an unmet need in the treatment of lichen planus, with a potential market opportunity exceeding $1 billion, underscoring Aclaris' strategic importance in fulfilling medical demands.
See More
Aclaris Therapeutics to Release Key Clinical Results
- Clinical Results Announcement: Aclaris Therapeutics is set to release clinical results for two of its leading immuno-inflammatory drug candidates before the U.S. market opens on April 28, 2026, marking a significant update in the company's biologic and oral inhibitor pipeline.
- Research Progress: The company will provide full results from its Phase 1a single and multiple ascending dose study of ATI-052, along with the lead indication selection for ATI-2138, demonstrating its ongoing commitment to research and development in immunotherapy.
- Stock Price Movement: Over the past year, ACRS has traded between $1.16 and $4.89, closing at $4.41 on Monday with a 2.56% increase, indicating positive market sentiment ahead of the upcoming results.
- Trading Activity: In after-hours trading, ACRS shares rose to $4.55, up 3.17%, reflecting investor confidence in the company's future prospects and heightened interest in the clinical results.
See More
Aclaris to Announce Phase 1a Trial Results Tomorrow
- Clinical Trial Results Announcement: Aclaris Therapeutics will announce the results of its Phase 1a trial for the anti-TSLP/IL-4R bispecific antibody ATI-052 before market opening on April 28, 2026, which is expected to provide critical clinical data that could influence the company's future R&D direction.
- Lead Indication Selection Process: The company will also disclose the results of its lead indication selection process for the ITK/JAK3 inhibitor ATI-2138, information that will help the market assess the potential of its product pipeline and may boost investor confidence.
- Webcast Arrangement: Aclaris will host a webcast and conference call at 8:30 AM EST on April 28, 2026, to provide detailed interpretations of the clinical data, enhancing communication with investors and increasing transparency.
- Caution on Forward-Looking Statements: The company cautions investors about the risks associated with forward-looking statements, including uncertainties in clinical trials and reliance on third parties, which could lead to significant discrepancies between actual results and expectations, impacting stock price volatility.
See More
Aclaris to Participate in Inflammatory Skin Disease Conference
- Executive Participation: Aclaris' CEO Neal Walker and senior leadership will participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference on April 14, 2026, showcasing the company's advancements in immuno-inflammatory diseases and aiming to enhance investor and public awareness of its R&D pipeline.
- Webcast Availability: The event will be accessible via a live and archived webcast on Aclaris' website for at least 30 days post-event, providing investors with convenient access to information and enhancing the company's transparency and public trust.
- R&D Pipeline Focus: Aclaris is dedicated to developing novel product candidates for immuno-inflammatory diseases, addressing the urgent need for effective treatment options, which highlights the company's innovative capabilities and market potential in the biopharmaceutical sector.
- Strategic Positioning: By participating in such industry conferences, Aclaris not only showcases its R&D strength but also strengthens connections with investors and industry experts, paving the way for future financing and collaboration opportunities.
See More
Aclaris Reports Significant Clinical Results for ATI-2138 in Atopic Dermatitis
- Significant Clinical Outcomes: At the 2026 American Academy of Dermatology Annual Meeting, Aclaris reported that patients receiving ATI-2138 showed a 77% improvement in Eczema Area and Severity Index (EASI) scores over 12 weeks, highlighting the drug's potential in treating atopic dermatitis.
- Multiple Metrics Improvement: The treatment group experienced a 70% improvement in affected body surface area, a 50% reduction in Peak Pruritus Numerical Rating Scale (PP-NRS) scores, and a 65% enhancement in Dermatology Life Quality Index (DLQI), further validating ATI-2138's broad applicability in immuno-inflammatory diseases.
- Good Tolerability: ATI-2138 demonstrated excellent tolerability at a low dose of 10 mg BID, achieving near-complete ITK target occupancy, which may reduce drug burden and enhance dosing flexibility for patients.
- Research and Development Potential: Aclaris's pipeline indicates that ATI-2138 is not only effective in atopic dermatitis but also holds promise for other immune-inflammatory diseases reliant on T cell function, supporting its potential as a best-in-class therapy.
See More
